Arcturus therapeutics joint venture mrna manufacturing partner, arcalis, awarded additional financial grants from japanese government

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a global late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, announced today that arcalis, arcturus' manufacturing joint venture in japan to support the production of mrna vaccines and therapeutics, has been selected by the japanese ministry of economy, trade and industry.
ARCT Ratings Summary
ARCT Quant Ranking